| Lannett Company, Inc. |
00527323737 |
LEVORPHANOL TARTRATE 3 mg Tablet 100 ct |
2021-01-21 |
6675.0000 |
Levorphanol Tartrate is a FDA approved treatment which Lannett’s approach will focus on educating healthcare professional staff on how to diagnose within the critical time window, and provide information about treatment with Levorphanol Tartrate. Educational materials will be provided across the patient journey, to both HCPs and to families, and highlight access and affordability support to ensure rapid access to therapy.
Levorphanol Tartrate has been developed for the treatment of patients and provides treatment options to delivers a safe, effective treatment. Levorphanol Tartrate is priced responsibly compared to similar agents with significant clinical benefit. Pricing accounts for development costs, complexity of manufacturing, distribution, and storage of product. Lannett demonstrates a strong commitment to patients and their ability to get access to care with support programs that leaves no patient behind. |
None |
96327 |
None |
None |
None |
None |
None |
None |
Lannett does not actively track estimated patients therefore the answer submitted is an estimate formulated by determining the estimated patient volumes for each indication and applying a market share factor to arrive at a final estimate for the product. |
None |
| Lannett Company, Inc. |
00527296443 |
CHLORPROMAZINE HCL 100 mg Tablet 1000 ct |
2021-02-02 |
5295.8600 |
Chlorpromazine is a FDA approved treatment which Lannett’s approach will focus on educating healthcare professional staff on how to diagnose within the critical time window, and provide information about treatment with Chlorpromazine. Educational materials will be provided across the patient journey, to both HCPs and to families, and highlight access and affordability support to ensure rapid access to therapy.
Chlorpromazine has been developed for the treatment of patients and provides treatment options to delivers a safe, effective treatment. Chlorpromazine is priced responsibly compared to similar agents with significant clinical benefit. Pricing accounts for development costs, complexity of manufacturing, distribution, and storage of product. Lannett demonstrates a strong commitment to patients and their ability to get access to care with support programs that leaves no patient behind. |
None |
59486 |
None |
None |
None |
None |
None |
None |
Lannett does not actively track estimated patients therefore the answer submitted is an estimate formulated by determining the estimated patient volumes for each indication and applying a market share factor to arrive at a final estimate for the product. |
None |
| Lannett Company, Inc. |
00527296543 |
CHLORPROMAZINE HCL 200 mg Tablet 1000 ct |
2021-02-02 |
7553.1500 |
Chlorpromazine is a FDA approved treatment which Lannett’s approach will focus on educating healthcare professional staff on how to diagnose within the critical time window, and provide information about treatment with Chlorpromazine. Educational materials will be provided across the patient journey, to both HCPs and to families, and highlight access and affordability support to ensure rapid access to therapy.
Chlorpromazine has been developed for the treatment of patients and provides treatment options to delivers a safe, effective treatment. Chlorpromazine is priced responsibly compared to similar agents with significant clinical benefit. Pricing accounts for development costs, complexity of manufacturing, distribution, and storage of product. Lannett demonstrates a strong commitment to patients and their ability to get access to care with support programs that leaves no patient behind. |
None |
59486 |
None |
None |
None |
None |
None |
None |
Lannett does not actively track estimated patients therefore the answer submitted is an estimate formulated by determining the estimated patient volumes for each indication and applying a market share factor to arrive at a final estimate for the product. |
None |
| Lannett Company, Inc. |
00527296243 |
CHLORPROMAZINE HCL 25 mg Tablet 1000 ct |
2021-02-02 |
2669.5500 |
Chlorpromazine is a FDA approved treatment which Lannett’s approach will focus on educating healthcare professional staff on how to diagnose within the critical time window, and provide information about treatment with Chlorpromazine. Educational materials will be provided across the patient journey, to both HCPs and to families, and highlight access and affordability support to ensure rapid access to therapy.
Chlorpromazine has been developed for the treatment of patients and provides treatment options to delivers a safe, effective treatment. Chlorpromazine is priced responsibly compared to similar agents with significant clinical benefit. Pricing accounts for development costs, complexity of manufacturing, distribution, and storage of product. Lannett demonstrates a strong commitment to patients and their ability to get access to care with support programs that leaves no patient behind. |
None |
59486 |
None |
None |
None |
None |
None |
None |
Lannett does not actively track estimated patients therefore the answer submitted is an estimate formulated by determining the estimated patient volumes for each indication and applying a market share factor to arrive at a final estimate for the product. |
None |
| Lannett Company, Inc. |
00527296343 |
CHLORPROMAZINE HCL 50 mg Tablet 1000 ct |
2021-02-02 |
3765.0500 |
Chlorpromazine is a FDA approved treatment which Lannett’s approach will focus on educating healthcare professional staff on how to diagnose within the critical time window, and provide information about treatment with Chlorpromazine. Educational materials will be provided across the patient journey, to both HCPs and to families, and highlight access and affordability support to ensure rapid access to therapy.
Chlorpromazine has been developed for the treatment of patients and provides treatment options to delivers a safe, effective treatment. Chlorpromazine is priced responsibly compared to similar agents with significant clinical benefit. Pricing accounts for development costs, complexity of manufacturing, distribution, and storage of product. Lannett demonstrates a strong commitment to patients and their ability to get access to care with support programs that leaves no patient behind. |
None |
59486 |
None |
None |
None |
None |
None |
None |
Lannett does not actively track estimated patients therefore the answer submitted is an estimate formulated by determining the estimated patient volumes for each indication and applying a market share factor to arrive at a final estimate for the product. |
None |
| LEADING PHARMA, LLC |
69315023203 |
Aminocaproic Acid Tabs 1000mg |
2021-03-16 |
713.4600 |
Generic product no pricing or marketing plan |
None |
33000 |
None |
None |
2016-04-16 |
None |
1 |
None |
This is an AB rated generic product that was developed by Carnegie Pharmaceuticals. Acquisition date was 4/16/2016 and price is not applicable. Additionally, as Leading Pharma sells generic products to wholesalers and retail pharmacies, we do not estimate the number of patients that may be prescribed our products neither by state or nationally, nor do we have access to any information which would indicate the number of patients in the United States with the condition(s) for which our products may be prescribed. We determine manufacturing volumes based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Leading Pharma subscribes to. Leading Pharma feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. |
None |
| Lupin Pharmaceuticals |
70748025807 |
Posaconazole DR Tablets 100mg x 60 |
2021-02-16 |
3289.4400 |
This is a partner product that we do not manufacture, but just help market and distribute. Price was determined by original owner, AET. |
None |
10000 |
None |
None |
None |
None |
None |
None |
This is a marketing agreement with the original manufacturer. We did not acquire the product, we just assist in marketing and distribution with a royalty sharing agreement in place. |
None |
| Lupin Pharmaceuticals |
70748015301 |
PENICILLAMINE TAB 250mg x 100 |
2021-03-01 |
4652.9200 |
Product has generic competition so pricing was determined to be competitive with current market contenders. |
None |
500 |
None |
None |
None |
None |
None |
None |
This product was internally developed by Lupin R&D. No acquisition to report. |
None |
| Lupin Pharmaceuticals |
43386040512 |
Nitazoxanide Tablets 500mg x 12 |
2021-03-03 |
1561.1000 |
WAC pricing was established at approximately a 14% discount to the Brand product. Contract pricing was negotiated at a customer specific level across our customer base. |
None |
3000 |
None |
None |
None |
None |
None |
None |
We did not acquire this drug. It is an AG of our own product in house. |
None |
| Lupin Pharmaceuticals |
43386040503 |
Nitazoxanide Tablets 500mg x 30 |
2021-03-05 |
3625.8100 |
WAC pricing was established at approximately a 14% discount to the Brand product. Contract pricing was negotiated at a customer specific level across our customer base. |
None |
3000 |
None |
None |
None |
None |
None |
None |
We did not acquire this drug. It is an AG of our own product in house. |
None |